Omada Health vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Omada Health is a virtual-first chronic care platform for diabetes, hypertension, and musculoskeletal conditions serving 2,000+ employer and health plan customers, with $170M 2024 revenue and a June 2025 Nasdaq IPO (OMDA).
About
Omada Health is a San Francisco-based digital health company founded in 2012 that offers virtual-first care programs for chronic conditions including prediabetes, Type 1 and Type 2 diabetes, hypertension, and musculoskeletal disorders. The platform combines human health coaches, licensed clinical practitioners, and connected devices—including cellular-enabled scales and continuous glucose monitors—with behavior science and clinical protocols to deliver personalized, data-driven care at scale. Omada describes its approach as "Compassionate Intelligence," integrating human relationships with AI-driven personalization.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.